E. Acute corneal hydrops
The patient was seen by ophthalmology who recommended admission for medical management to prevent further self-inflicted trauma via clear plastic shields and initiate eye drops including atropine, prednisolone, and hypertonic saline. Once parents were comfortable administering drops at home, the patient was discharged a few days later with close out-patient ophthalmology follow-up. Eventually ophthalmic losartan was added with great improvement. It took two months for the patient to completely recover.
The term “hydrops” originates from the ancient Greek word “húdōr,” which means “water,” and is used in medicine to refer to any abnormal accumulation of serous fluid in a tissue or cavity. In the case of acute corneal hydrops, there is a break in the Descment membrane and endothelium, and aqueous humor influxes causing corneal edema. Conditions that weaken the cornea increase the risk of this condition and includes keratoconus (progressive thinning and cone-like steepening of the cornea. Patients with trisomy 21, atopic disease, learning disabilities, corneal anatomical variances, steep keratometry, and elevated intraocular pressure are also at increased risk of acute corneal hydrops. Eye rubbing also increases risk.
Symptoms of acute corneal hydrops includes sudden onset of decreased visual acuity, photophobia, pain, and a translucent milky-white appearance to the cornea. Diagnosis is made based on history and slit lamp findings. Medical management includes hypertonic saline drops to draw fluid from the epithelium, topical antibiotics to prevention secondary infection, antiglaucoma medications to reduce hydrodynamic forces, as well as cycloplegics, NSAIDs, and steroids to help with symptoms. Surgical treatment may also play a role and include intracameral gas injection, compression corneal sutures, and penetrating keratoplasty. While most cases spontaneously resolve in 2- 4 months, complications may include vision-debilitating scarring, infection, pseudocyst formation, and corneal perforation.
References
Mudgil T, Nagpal R, Goel S, Basu S. Acute Corneal Hydrops: Etiology, Risk Factors, and Management. In: Das S, ed. Keratoconus. Singapore: Springer; 2022. doi:10.1007/978-981-19-4262-4_12.
Barsam A, Petrushkin H, Brennan N, et al. Acute corneal hydrops in keratoconus: a national prospective study of incidence and management. Eye (Lond). 2015;29(4):469-474. doi:10.1038/eye.2014.333
Barsam A, Brennan N, Petrushkin H, et al. Case-control study of risk factors for acute corneal hydrops in keratoconus. Br J Ophthalmol. 2017;101(4):499-502. doi:10.1136/bjophthalmol-2015-308251
McMonnies CW. Mechanisms for acute corneal hydrops and perforation. Eye Contact Lens. 2014;40(4):257-264. doi:10.1097/ICL.0000000000000048
Fan Gaskin JC, Patel DV, McGhee CN. Acute corneal hydrops in keratoconus – new perspectives. Am J Ophthalmol. 2014;157(5):921-928. doi:10.1016/j.ajo.2014.01.017
Maharana PK, Sharma N, Vajpayee RB. Acute corneal hydrops in keratoconus. Indian J Ophthalmol. 2013;61(8):461-464. doi:10.4103/0301-4738.116062
García de Oteyza G, Bregliano G, Sassot I, Quintana L, Rius C, García-Albisua AM. Primary surgical options for acute corneal hydrops: A review. Eur J Ophthalmol. 2021;112067212110378. doi:10.1177/11206721211037833
Ocular Trauma: Acute Evaluation, Cataract, Glaucoma. EyeWiki.https://eyewiki.org/Ocular_Trauma:_Acute_Evaluation,_Cataract,_Glaucoma. Accessed June 18, 2024.
Bacterial Keratitis. EyeWiki. https://eyewiki.aao.org/Bacterial_Keratitis#References. Published June 3, 2021. Accessed June 18, 2024.
Fuchs’ Endothelial Dystrophy. EyeWiki.https://eyewiki.aao.org/Fuchs%E2%80%99_Endothelial_Dystrophy#:~:text=Disease-,Fuchs’%20endothelial%20dystrophy%20is%20a%20non%2Dinflammatory%2C%20sporadic%20or,halos%2C%20and%20reduced%20visual%20acuity. Accessed June 18, 2024.
American Academy of Ophthalmology. Acute Anterior Uveitis. EyeWiki.https://eyewiki.aao.org/Acute_Anterior_Uveitis. Accessed June 20, 2024.
Wilson SE. Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders. J Ocul Pharmacol Ther. 2023;39(3):191-206. doi:10.1089/jop.2022.0174